glp-1 drugs heart failure Can for protection in Autoimmune Disease? GLP-1 medications are not just
Description
Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss
GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective anti-glycemic and weight-loss medications with a strong safety record
What to expect
The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.
Without getting too deep into the science, glucagon-like peptide-1, or GLP-1, is a hormone
